Zalicus Granted Composition-of-Matter Patent for Z944

  Zalicus Granted Composition-of-Matter Patent for Z944

        Key Patent Provides Broad Coverage for Z944 through April 2029

Business Wire

CAMBRIDGE, Mass. -- February 20, 2013

Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that it has been granted a patent by the U.S. Patent and
Trademark office (USPTO) covering its product candidate Z944. United States
patent number 8,377,968 entitled “N-Piperidinyl Acetamide Derivatives as
Calcium Channel Blockers” provides broad coverage for Z944 including
compositions of matter and certain therapeutic methods of use through April
2029. Z944 is a novel, oral, T-type calcium channel blocker which has
demonstrated efficacy in a number of preclinical inflammatory pain models and
other disease models. Z944 completed Phase 1 single and multiple ascending
dose clinical studies in late 2012 and the Company plans to continue further
clinical development with Z944 during 2013.

“This key patent provides the foundation of a solid and enforceable
intellectual property estate for Z944, with issued claims through April 2029,”
commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Based on our
preclinical and early-stage clinical work, we are excited to further explore
the potential of Z944 as a novel, oral, non-opioid pain treatment.”

About Zalicus

Zalicus Inc. (Nasdaq Global Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates, their potential, and its plans for clinical development.
These forward-looking statements about future expectations, plans, objectives
and prospects of Zalicus and its product candidates may be identified by words
like "believe," "expect," "may," "will," "should," "seek," “plan” or “could”
and similar expressions and involve significant risks, uncertainties and
assumptions, including risks related to the clinical development of its
product candidates, the unproven nature of the Zalicus Ion channel drug
discovery technology, and those other risks that can be found in the "Risk
Factors" section of Zalicus' annual report on Form 10-K on file with the
Securities and Exchange Commission and the other reports that Zalicus
periodically files with the Securities and Exchange Commission. Actual results
may differ materially from those Zalicus contemplated by these forward-looking
statements. These forward-looking statements reflect management’s current
views and Zalicus does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or circumstances that
occur after the date of this release except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.


Zalicus Inc.
Justin Renz, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.